The Departments of Laboratory Medicine and Hematology entered into a partnership with the Social impact foundation MWH4impact on Natural Killer cell therapy.
In a 4-year program MWH4impact financially supports specialized staff to enable the “market-readiness” of the promising Natural Killer (NK) cell therapy product developed in the Radboudumc. This involves the upscaling and implementation strategy of an off-the-shelf NK cell product generated from umbilical cord blood stem cells.
Harry Dolstra, (photo above), Joop Jansen and their team, theme Cancer development and immune defense, have succeeded in growing these NK cells from stem cells in large numbers. They received grants from KWF to examine in patients whether these NK cells can effectively combat leukemia and ovarian cancer cells. Together with MWH4impact they are in an unique position to further develop and bring the NK cell therapy to patients with cancer.
Related news items
Brain specific mutations may only explain sporadic Alzheimer's disease in very few cases20 August 2018
Alexander Hoischen, theme Infectious diseases and global health, and colleagues studied brain- and blood-DNA of sporadic early-onset Alzheimer’s disease (AD) patients, for somatic mutations in the known AD genes.read more
Poster prize Lars Damen at 10th European Elastin Meeting17 August 2018
At the 10th European Elastin Meeting, Lars Damen, theme Reconstructive and regenerative medicine, received the early-stage researcher award for his poster entitled “Development of tools to study the sulfation pattern of heparan sulfate involved in elastic fiber biology”.read more
Merel Ritskes member of the 3RCC Scientific Advisory Board8 August 2018
The 3RCC Scientific Advisory Board is responsible for providing scientific expertise to the 3RCC, evaluating grant applications and evaluating the progress and functioning of the center.read more